Showing results (2221-2230 of 4,542) with videos related to
Sort By:
Pageof 455
Journal of Gastroenterology|February 1, 2026
Agonistic GITR treatment enhances antitumor immune responses and suppresses tumor progression in pancreatic ductal adenocarcinomaSteve Robatel, Hanne Hillen, Ivanina Mutisheva, et al.Journal of Gastroenterology|February 6, 2026
Intestinal obstruction impairs the antitumor function of hepatic natural killer cells against colorectal cancerKouki Imaoka, Masahiro Ohira, Takuya Yano, et al.Journal of Gastroenterology|February 6, 2026
HLA-DQB1*03:01 and HLA-DQA1*05:05 as key genetic determinants of infliximab response and immunogenicity in Japanese patients with inflammatory bowel diseaseRyuya Osaka, Takeo Naito, Seik-Soon Khor, et al.Journal of Gastroenterology|February 14, 2026
Escherichia coli as a gut microbial marker of obesity and its reduction following bariatric treatmentTomoyuki Hayashi, Noriho Iida, Kohei Yasuda, et al.Journal of Gastroenterology|February 3, 2026
YAP1-driven tumor-like cancer-associated fibroblasts modulate biomechanics of pancreatic ductal adenocarcinomaAoran Yang, Chen Pan, Chengli Gu, et al.Journal of Gastroenterology|March 20, 2025
Myeloid-derived MANF ameliorates ethanol-induced liver injury by enhancing microRNA-223 expressionHuiyuan Xie, Pingping Zhang, Shanru Yang, et al.Journal of Gastroenterology|April 12, 2025
Educational interventions to enhance support for balancing work and treatment in inflammatory bowel disease patientsNobuhiro Ueno, Aki Sakatani, Katsuyoshi Ando, et al.Journal of Gastroenterology|February 25, 2026
Single-cell transcriptomics unveils the immunologic landscape of anti-PD-1-associated indirect drug-induced liver injuryJinjing Wu, Haizhou Miao, Weiliang Yuan, et al.Journal of Gastroenterology|February 19, 2026
Targeting the ZDHHC9-mediated STAT1 palmitoylation-phosphorylation conversion inhibits gastric cancer progressionXiao Bai, Yun-Ran Guo, Wan-Chuan Zhang, et al.Journal of Gastroenterology|February 21, 2026
A phase I/II clinical trial of neoadjuvant docetaxel/oxaliplatin/S‑1 (DOS) combination therapy for gastroesophageal junction adenocarcinomaKoshi Kumagai, Kei Hosoda, Chikatoshi Katada, et al.Pageof 455